Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

32.00
+0.79002.53%
Pre-market: 31.86-0.1400-0.44%04:25 EDT
Volume:1.26M
Turnover:40.14M
Market Cap:3.82B
PE:-6.04
High:32.26
Open:31.16
Low:30.81
Close:31.21
Loading ...

Fady Ibraham Malik, EVP of Research & Development, Reports Disposal of Cytokinetics Common Shares

Reuters
·
13 hours ago

Top Executive Sells Cytokinetics Shares in Lucrative Deal!

TIPRANKS
·
7 hours ago

Cytokinetics CEO Robert I. Blum Reports Disposal of Common Shares

Reuters
·
Yesterday

Mizuho Securities Remains a Buy on Cytokinetics (CYTK)

TIPRANKS
·
29 May

Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating

MT Newswires Live
·
29 May

Cytokinetics Inc : Mizuho Cuts Target Price to $84 From $103

THOMSON REUTERS
·
29 May

Top Executive Sells Thousands of Cytokinetics Shares!

TIPRANKS
·
21 May

Fady Ibraham Malik, EVP Research & Development, Reports Disposal of Common Shares of Cytokinetics Inc

Reuters
·
21 May

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

THOMSON REUTERS
·
18 May

Cytokinetics CEO Robert I. Blum Reports Disposal of Common Shares

Reuters
·
17 May

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
17 May

Cytokinetics Director Makes Strategic Stock Sale!

TIPRANKS
·
16 May

Cytokinetics Director Muna Bhanji Reports Disposal of Common Shares

Reuters
·
16 May

BUZZ-Biohaven drops after FDA extends review period for genetic disease drug

Reuters
·
15 May

Cytokinetics Price Target Maintained With a $72.00/Share by Needham

Dow Jones
·
14 May

BUZZ-U.S. STOCKS ON THE MOVE-GE Vernova, Alliant Energy, Boeing

Reuters
·
13 May

Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position

TIPRANKS
·
13 May

Stock Track | Cytokinetics Plummets 5.01% Despite Positive Trial Results, FDA Delay Concerns Linger

Stock Track
·
13 May

Cytokinetics Shares up 1.5% After Heart Disease Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
13 May

BUZZ-U.S. STOCKS ON THE MOVE-Oddity Tech, Under Armour, Cytokinetics

Reuters
·
13 May